Eli Lilly news covering GLP-1 drugs Mounjaro and Zepbound, obesity and diabetes pipeline, earnings, and Lilly's race with Novo Nordisk.
Eli Lilly is set to showcase new research on its cardiometabolic portfolio at the EASD 2026 meeting in Milan. Key presentations include Phase 3 data for the triple agonist retatrutide, safety updates for the oral drug Foundayo, and initial findings on the investigational treatment eloraTZP.
The commentary analyzes Eli Lilly's strategy to expand access to obesity drugs like Zepbound through Medicare Bridge programs, arguing this approach supports its investment narrative despite risks from reimbursement pressures. It suggests that broadening access is central to sustaining earnings growth and justifying the company's premium valuation.